SCHEMBL11944731

SCHEMBL11944731

CC(C)S(=O)(=O)N1CCN(c2cnn(-c3cccc(Cl)c3)c(=O)c2OC2CCC2)CC1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2C19 P33261 1/20 0.49
PPARG P37231 1/20 0.49
NCOA2 Q15596 1/20 0.49
NCOA1 Q15788 1/20 0.49
NPSR1 Q6W5P4 1/20 0.49
NCOA3 Q9Y6Q9 1/20 0.49
ALDH1A1 P00352 4/20 0.45
DCTPP1 Q9H773 1/20 0.45
MAPT P10636 2/20 0.44
MCHR1 Q99705 4/20 0.41
NPBWR1 P48145 3/20 0.41
TNF P01375 1/20 0.41
LITAF Q99732 1/20 0.41
KDM4E B2RXH2 1/20 0.41
PKM P14618 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
CACNB4 O00305 2/20 0.41
CACNA1A O00555 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11943959 0.98 POLB (0.49) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944263 0.97 POLB (0.49) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944034 0.97 POLB (0.49) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944128 0.93 POLB (0.46) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944105 0.93 POLB (0.47) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11945236 0.93 POLB (0.48) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11945119 0.93 POLB (0.48) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11943961 0.93 POLB (0.48) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944160 0.93 POLB (0.47) POLBCYP3A4CYP2C19PPARGNCOA2
SCHEMBL11944217 0.93 POLB (0.45) POLBCYP3A4CYP2C19PPARGNCOA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-8232274-B2 Pyridazinone derivatives useful as glucan synthase inhibitors ALBANY MOLECULAR RESEARCH, INC. (US) 2012-07-31 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors SCHERING CORPORATION AND ALBANY MOLECULAR RESEARCH, INC. 2009-07-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090170861-A1 Pyridazinone Derivatives Useful as Glucan Synthase Inhibitors MAN2A1, GYS2, MANBA POLB 1088/4885CYP3A4 281/4885CYP2C19 461/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.